ARTICLE | Company News

Arcturus, Synthetic Genomics partner for RNA-based vaccines

December 1, 2017 9:54 PM UTC

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) granted Synthetic Genomics Inc. (La Jolla, Calif.) exclusive, worldwide rights to its LUNAR lipid-mediated delivery technology to develop self-amplifying RNA-based vaccines and therapeutics for humans and animals based on Synthetic Genomics' RNA replicon platform.

Arcturus received an upfront payment and is eligible for milestones and royalties. Synthetic will provide R&D support. Arcturus declined to disclose financial details , while Synthetic did not respond to inquiries...